Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M.

J Clin Oncol. 2011 Jun 10;29(17):2372-7. doi: 10.1200/JCO.2010.33.0688. Epub 2011 May 9.

PMID:
21555696
2.

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M.

Mod Pathol. 2010 Jun;23(6):824-33. doi: 10.1038/modpathol.2010.58. Epub 2010 Mar 19.

3.

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.

Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC.

J Clin Oncol. 2004 Dec 1;22(23):4762-71. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570077
4.

DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients.

Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de Herder W, de Krijger RR, Verhofstad AA, Hermus AR, Kummer JA, Skogseid B, Volante M, Voogd AC, Ramaekers FC, Speel EJ.

Endocr Relat Cancer. 2007 Sep;14(3):769-79.

5.

Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.

Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M.

Dig Liver Dis. 2009 Jan;41(1):49-55. doi: 10.1016/j.dld.2008.03.015. Epub 2008 May 7.

PMID:
18463008
6.

Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E, Tzivras M, Sougioultzis S, Papastratis G, Karatzas G, Papalambros E, Tsavaris N.

Anticancer Res. 2008 Jan-Feb;28(1B):543-9.

7.

Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.

Müller MW, Friess H, Köninger J, Martin D, Wente MN, Hinz U, Ceyhan GO, Blaha P, Kleeff J, Büchler MW.

Am J Surg. 2008 Feb;195(2):221-8.

PMID:
18154768
8.

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy.

Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T.

Pancreas. 1996 Apr;12(3):267-71.

PMID:
8830333
9.

Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.

Seo Y, Kim MS, Yoo S, Cho C, Yang K, Yoo H, Choi C, Lee D, Kim J, Kim MS, Kang H, Kim Y.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1456-61. doi: 10.1016/j.ijrobp.2009.01.042. Epub 2009 Sep 23.

PMID:
19783379
10.

Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer.

Clark CJ, Traverso LW.

Am J Surg. 2010 May;199(5):657-62. doi: 10.1016/j.amjsurg.2010.01.021.

PMID:
20466112
11.

Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.

Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC.

Cancer. 2009 Feb 1;115(3):665-72. doi: 10.1002/cncr.24059.

12.

Telomerase activity in pancreatic endocrine tumors.

Tang SJ, Dumot JA, Wang L, Memmesheimer C, Conwell DL, Zuccaro G, Goormastic M, Ormsby AH, Cowell J.

Am J Gastroenterol. 2002 Apr;97(4):1022-30.

PMID:
12003383
13.

A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.

Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB 3rd.

Am J Clin Oncol. 2007 Feb;30(1):26-31.

PMID:
17278891
14.

Microwave ablation in locally advanced pancreatic carcinoma--a new look.

Lygidakis NJ, Sharma SK, Papastratis P, Zivanovic V, Kefalourous H, Koshariya M, Lintzeris I, Porfiris T, Koutsiouroumba D.

Hepatogastroenterology. 2007 Jul-Aug;54(77):1305-10.

PMID:
17708242
15.

Pancreatic head carcinoma: clinical analysis of 189 cases.

Hua YP, Liang LJ, Peng BG, Li SQ, Huang JF.

Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):79-84.

16.

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G.

Endocr Relat Cancer. 2005 Dec;12(4):1083-92.

17.

Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure.

Zimmermann FB, Schuhmacher C, Lersch C, Bernhardt B, Pickel P, Siewert JR, Molls M, Jeremic B.

Hepatogastroenterology. 2004 Nov-Dec;51(60):1842-6.

PMID:
15532839
18.

Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors.

Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V.

Mod Pathol. 2009 Jul;22(7):933-9. doi: 10.1038/modpathol.2009.50. Epub 2009 Apr 17.

19.

Nuclear markers (star volume, mitotic index, AgNOR and Ki-67) of the primary tumor and its metastasis in non-small cell lung carcinomas.

Matheus RS, Bernardi Fdel C, Gallo CP, da Silva AP, Rodrigues OR, Capelozzi M, Lopes A, Fenezelian S, Saldiva PH, Capelozzi VL.

Pathol Res Pract. 2004;200(1):13-23.

PMID:
15157046
20.

Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma.

von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C.

Thromb Haemost. 2007 Aug;98(2):434-9.

PMID:
17721628

Supplemental Content

Support Center